Cite
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
MLA
Nelde, Annika, et al. “HLA Class I-Restricted MYD88 L265P-Derived Peptides as Specific Targets for Lymphoma Immunotherapy.” Oncoimmunology, vol. 6, no. 3, Dec. 2016, p. e1219825. EBSCOhost, https://doi.org/10.1080/2162402X.2016.1219825.
APA
Nelde, A., Walz, J. S., Kowalewski, D. J., Schuster, H., Wolz, O.-O., Peper, J. K., Cardona Gloria, Y., Langerak, A. W., Muggen, A. F., Claus, R., Bonzheim, I., Fend, F., Salih, H. R., Kanz, L., Rammensee, H.-G., Stevanović, S., & Weber, A. N. R. (2016). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology, 6(3), e1219825. https://doi.org/10.1080/2162402X.2016.1219825
Chicago
Nelde, Annika, Juliane Sarah Walz, Daniel Johannes Kowalewski, Heiko Schuster, Olaf-Oliver Wolz, Janet Kerstin Peper, Yamel Cardona Gloria, et al. 2016. “HLA Class I-Restricted MYD88 L265P-Derived Peptides as Specific Targets for Lymphoma Immunotherapy.” Oncoimmunology 6 (3): e1219825. doi:10.1080/2162402X.2016.1219825.